- Home
- About mondoBIOTECH
- Investors
- Corporate Fact Sheet
- Company Presentation
- All Reports
- Corporate Governance
- Share Information
- Financial Calendar
- Shareholders’ Meeting
- Investor Relation Contact
- Media Releases
- Business Partners
- Pipeline
- Community
- Careers
- Contact Us
Search
| Investors - Media Releases | ||
| Stay Informed | ||
|
2008
| ||
| December 02, 2008 |
| Swiss Innovation Award 2008 |
| The Swiss Innovation Award 2008 was awarded to Mondobiotech AG by the Central Swiss Chamber of Commerce in the monastery dasKloster in Stans. |
| November 30, 2008 |
| Acute effects of inhaled Aviptadil in patients with chronic pulmonary hypertension. |
| In a recent publication in The European Respiratory Journal (2008 Nov;32(5):1289-94), the beneficial effects of inhaled Aviptadil in patients with chronic pulmonary hypertension have been described. |
| September 27, 2008 |
| The Next Wave in Life Sciences |
Genetics and regenerative medicine are set to dramatically change approaches and attitudes towards disease and ageing.
mondoBIOTECH will discuss on 27/28. September 2008 at the Word Economic Forum, Annual Meeting of the new Champions 2008 the latest developments in life sciences with those at the forefront of research innovation and real world applications in this field.
|
| July 13, 2008 |
| Every ace for a good cause, ASO Gstaad |
The Allianz Suisse Open Gstaad paid, under the leadership of Mondobiotech, an amount of CHF 50 for each achieved ace during the tournament. The total amount of 17'000 CHF (340 aces) went as a donation to Prof. Maurice Beghetti from the university-clinic Geneva (Chief of the Pediatric cardiology department) to the use for research and treatment of rare diseases with children. |
| June 11, 2008 |
| mondoBIOTECH moves into the monastery – phase 1 |
Opening of our office in Stans, 4 July 2008
A first step towards the monastery.
The Mondobiotech clinical development team from Zug will move on July 4th into their new provisory office spaces on the grounds of the former capuchin monastery in Stans.
The renovations for the monastery are in the planning phase at the moment. The complete reconstruction shall be terminated in the summer of 2010.
The new Mondobiotech World center for rare and neglected diseases will play a pioneer role in the research and development of new drugs for rare diseases. The canton Nidwalden shall get positive impact and attention in economic and social respects through this. |
| May 16, 2008 |
| mondoBIOTECH presents clincal trial result at ATS 2008 |
|
Basel, May 16, 2008 - mondoBIOTECH, a private Swiss biotechnology company, today announced that the data from the clinical trial “AVICUTE - Aviptadil in Pulmonary Hypertension” will be presented on Sunday, May 18, 2008 at the 2008 ATS International Conference in Toronto, Canada at the session “DIAGNOSIS, TREATMENT, AND PROGNOSIS OF PULMONARY HYPERTENSION” from 1:30 pm to 4:15 pm.
“Twenty patients with pulmonary hypertension of different etiologies, either medication naive or treated with different approved PAH medicaments, were included in this clinical phase II study. Patients received a single dose of 100 micrograms of Aviptadil (Vasoactive Intestinal Peptide) during right heart catheter testing" commented Dorian Bevec, Chief Scientific Officer of mondoBIOTECH “All patients tolerated Aviptadil inhalation well with no apparent serious negative side effects. Acute hemodynamics and blood gases were measured at baseline, at the end of inhalation, and every 15 minutes thereafter for another hour. Aviptadil inhalation leads to pulmonary vasodilation and a reduced workload of the right heart ventricle. This is observed not only in IPAH patients, but also in non-IPAH patients. Importantly, Aviptadil inhalation improved oxygenation in patients with chronic lung diseases underlying Pulmonary Hypertension.”
About Aviptadil
Aviptadil is a synthetically produced version of the endogenous human peptide Vasoactive Intestinal Peptide (VIP). Its biological role has been widely researched in a variety of diseases and in healthy situations. Aviptadil is produced by neurons, by endocrine cells, as well as by cells of the immune system. In scientific literature, Aviptadil is considered as one of the body’s ‘Molecules that Protect’. Aviptadil received Orphan Medicinal Product Designation status for Pulmonary Arterial Hypertension, Acute Lung Injury, and Sarcoidosis in the European Union, and for Pulmonary Arterial Hypertension and Acute Respiratory Distress Syndrome in the USA. mondoBIOTECH entered an exclusive collaboration and license agreement with Biogen Idec to develop, manufacture and commercialize Aviptadil for the treatment of Pulmonary Arterial Hypertension.
|
| April 16, 2008 |
| round table event, Kloster Stans |
“Why a monastery for Mondobiotech?”
Mondobiotech decided to move its Headquarters into the monastery of Stans in order to become the first world center for rare and neglected diseases, along with new jobs, and a place of great inspiration for the international exchange of expert knowledge amongst scientists and experts from all over the world.
In the round table which took place at the monastery in Stans, on April 16, 2008, renowned international experts discussed the topic “Why is Mondobiotech entering a monastery and does it make sense?”.
Key opinion leaders and guest speakers from the religious side, from science and medicine, patients’ organizations and local politics confronted their opinion and vision with the Mondobiotech representatives. |
| January 28, 2008 |
| The growth of mondoBIOTECH will be in the former Capuchin Monastery in Stans |
| Basel, 28 January 2008 – The Mondobiotech Group today announces that, at its meeting of 23 January 2008, the cantonal parliament of Nidwalden granted Mondobiotech the leasehold on the former Capuchin monastery in Stans for the next 60 years. "We express our deepest gratitude to the government and the parliament of Nidwalden for the overwhelming approval of the leasehold”, says Fabio Cavalli, Chief Executive Officer of Mondobiotech. "We are extremely pleased that Canton Nidwalden has embraced the spirit enshrined in the “Power of Collaborative Innovation” of the World Economic Forum 2008, in which Mondobiotech has been taking part as a Technology Pioneer. The former monastery in Stans will be a great help on future paths of research into new treatments for patients affected by rare diseases. All further future plans will be presented at a round-table meeting with international guests on 16 April 2008. The venue, date and participants will be announced 4 weeks beforehand at www.mondobiotech.com. Information on Mondobiotech Mondobiotech is a Swiss biopharmaceutical company engaged in developing and marketing substances that occur naturally in the body as therapeutic agents for the treatment of life-threatening and rare diseases. For more information: www.mondobiotech.com |
